Volume 9 Supplement 2

Parasite to Prevention: Advances in the understanding of malaria

Open Access

Identification of genetic markers of resistance to Artemisinin Combination Therapy in the rodent model Plasmodium chabaudi

  • Louise A Rodrigues1,
  • Gisela Henriques1,
  • Sofia T Borges1,
  • Paul Hunt2,
  • Cecília P Sanchez3,
  • Axel Martinelli1 and
  • Pedro Cravo1
Malaria Journal20109(Suppl 2):O26

https://doi.org/10.1186/1475-2875-9-S2-O26

Published: 20 October 2010

Background

Effective treatment of malaria relies mostly on Artemisin Combination Therapy (ACT), which consists of the administration of an Artemisinin (ART) derivative in conjunction with a chemically unrelated anti-malarial, such as Mefloquine (MF). ACTs should reduce the chances of a parasite carrying mutations conferring resistance to both drugs [1]. However, parasites resistant to the different components of the combination have recently been reported. For instance, in Southeast Asia, the appearance of parasites showing increased in vivo tolerance to artesunate (ATN) [2, 3] may undermine the future efficacy of the ATN+MF combination.

We have previously selected stable resistance to ATN in the rodent malaria parasite Plasmodium chabaudi[4]. ATN-resistant parasites showed a mutation on pcubp1 gene, coding fora deubiquitinating enzyme [5]. No changes were found in thepcatp6 and and pcmdr1 genes [4].

In order to study the genetics of resistance to ACTs, the ATN-resistant P.chabaudi clone was repeatedly sub-inoculated into mice continuously treated with ATN + MF. Upon reaching a certain level of resistance, parasites were cloned by limiting dilution. The parasites' genetic background was investigated by SOLEXA whole genome re-sequencing. The identified mutations were confirmed by dideoxy sequencing real-time polymerase chain reaction.

Results

Selection and cloning procedures originated five parasite clones, of which only one, denoted AS-ATNMF-1, was investigated. When compared to the ATN-resistant progenitor, AS-ATNMF-1 is resistant to treatment with the combination of both ATN+MF, as well as to each drug separately.

AS-ATNMF-1 carries three distinctive mutations one of which is a duplication of the mdr1 gene. The remaining two mutations are SNPs in genes of unknown function and remain to be further investigated. No differences were found in the coding sequences of pcatp6 and pcubp1 when comparing AS-ATNMF-1 and its progenitor.

Conclusions

This work provides strong evidence to support the possibility of the emergence of resistance to ACTs, even when the two drugs of the combination are administered simultaneously. Additionally, duplication of the mdr1 gene may play a role in mediating ATN + MF resistance. However, the presence of other mutations seems to be required for the expression of this phenotype.

Authors’ Affiliations

(1)
Centro de Malária e Outras DoençasTropicais/IHMT/UNL, UEI Biologia Molecular, UEI Malária
(2)
Centre for Immunity, Infection and Evolution, School of Biological Science, The University of Edinburgh
(3)
Hygiene Institut, Abteilung Parasitologie, Universita tsklinikum Heidelberg

References

  1. White N: Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999, 354: 739-49. 10.1098/rstb.1999.0426.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F: Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009, 4: e455-10.1371/journal.pone.0004551.View ArticleGoogle Scholar
  3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White N: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-67. 10.1056/NEJMoa0808859.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, do Rosário V, Cravo P: Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother. 2006, 50: 480-9. 10.1128/AAC.50.2.480-489.2006.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Hunt P, Afonso A, Creasey A, Culleton R, Sidhu AB, Logan J, Valderramos SG, McNae I, Cheesman S, do Rosario V, Carter R, Fidock DA, Cravo P: Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol. 2007, 65: 27-40. 10.1111/j.1365-2958.2007.05753.x.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Rodrigues et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement